EP3158991
Samsetningar af bendamústín
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
28.1.2011EP published:
17.3.2021EP application number:
16020363.4
EP translation filed:
15.6.2021Grant published:
15.7.2021EPO information:
European Patent Register
Max expiry date:
27.1.2031Expiry date:
27.1.2027Next due date:
31.1.2027
Title:
FORMULATIONS OF BENDAMUSTINE
Timeline
Today
28.1.2011EP application
17.3.2021EP Publication
15.6.2021Translation submitted
15.7.2021Registration published
27.1.2027Expires
Owner
Name:
Eagle Pharmaceuticals, Inc.Address:
50 Tice Boulevard, Woodcliff Lake, NJ 07677, US
Inventor
Name:
Palepu, Nagesh R.Address:
Southampton, Pennsylvania 18966, US
Name:
Buxton, Philip ChristopherAddress:
Great Dunmow, Essex CM6 2PB, GB
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
299100 PDate:
28.1.2010Country:
US
Classification
Categories:
A61K 9/08, A61K 31/4184, A61K 47/10, A61K 47/20, A61P 35/00
Annual fees
Number
Paid
Expires
Payer
Number: 12
Paid: 31.12.2021
Expires: 27.1.2023
Payer: Patice ehf.
Number: 13
Paid: 3.1.2023
Expires: 27.1.2024
Payer: Árnason Faktor ehf.
Number: 14
Paid: 4.1.2024
Expires: 27.1.2025
Payer: Árnason Faktor ehf.
Number: 15
Paid: 8.1.2025
Expires: 27.1.2026
Payer: Árnason Faktor ehf.
Number: 16
Paid: 20.1.2026
Expires: 27.1.2027
Payer: Árnason Faktor ehf.